Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06933381 · ClinicalTrials.gov registry record · NA
Vapocoolant Spray to Reduce Pain With Nexplanon Insertion
A NA study of Reducing Pain With Nexplanon Implant Insertion, sponsored by Queen's Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 3
- Study locations
NCT06933381: Recruiting NA study of Reducing Pain With Nexplanon Implant Insertion, sponsored by Queen's Medical Center.
NCT06933381 is a NA study of Reducing Pain With Nexplanon Implant Insertion that is actively recruiting participants, run by Queen's Medical Center. The registered enrollment target is 70 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06933381, a NA study of Reducing Pain With Nexplanon Implant Insertion, is actively recruiting participants, sponsored by Queen's Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.
Primary Outcome
The investigators will ask patients to rate their pain with lidocaine injection that precedes Nexplanon insertion using a visual analog scale (VAS). The visual analog scale is a 100 mm line, with values 0 to 100. 0 is marked as no pain and 100 is marked as worst pain.
Conditions Studied
Interventions
- OTHER Placebo
- DEVICE Vapocoolant spray
Study Locations (3)
Hawaii
- Queens Medical Center POB 2 Suite 402 - Honolulu
- Queens Medical Center POB1 Clinic 1004 - Honolulu
- Women's Center Queen's North Hawai'i Community Hospital Suite #124 and #120 - Waimea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2026-05-01 |
| Phase | NA |
What NCT06933381 shows while recruiting
NCT06933381 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Reducing Pain With Nexplanon Implant Insertion appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06933381 reports a single indexed study location in Hawaii.
Frequently Asked Questions
What is clinical trial NCT06933381 about?
NCT06933381 is a clinical study titled "Vapocoolant Spray to Reduce Pain With Nexplanon Insertion". The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.
What is the current status of trial NCT06933381?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2025-06-16. Estimated completion is 2026-05-01.
What conditions does trial NCT06933381 study?
This clinical trial studies the following conditions: Reducing Pain With Nexplanon Implant Insertion.
What interventions are being tested in trial NCT06933381?
The interventions under investigation include: Placebo (OTHER), Vapocoolant spray (DEVICE).
Who is sponsoring clinical trial NCT06933381?
This trial is sponsored by Queen's Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06933381 being conducted?
This trial has 3 study locations across Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06933381's enrollment target sits among peer trials
70 1103rd of 2000 higher than 868 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI